Responsible for translational and early development activities across Bayer's immune oncology and oncogenic signaling platforms. This includes functional leadership of the global clinical pharmacology and clinical development lead groups and the China Translational Medicine Oncology team. Support BD&L efforts to expand pipeline through partnerships and in licensing, and JSC member for a number of discovery collaborations. Member of the Bayer global leadership circle.

Head of the Department of Biological Sciences: responsible for over 50 pre-clinical and translational scientists covering protein sciences, structural biology, screening, functional genomics, in vitro and in vivo disease modelling and electrophysiology. Member of the UK site executive team and interim head of the UK research facility.Co-chair (research lead) of the global oncology franchise covering a portfolio of immune oncology and precision medicine small molecule approaches.Oncology program head for multiple pre-clinical, Ph1 and Ph2 candidates.Global head of hemoglobinopathy portfolio, with oversight of CTX001 a novel CRISPR/Cas9 gene edited cell therapy for sickle cell and betathalasemia.Global head of a kidney disease and a neurodegeneration pre-clinical portfolio. Initiated and lead numerous collaborations across the industry and with leading academic centers.Member of the Diamond Light Source Industry Steering Committee, Scientific Advisory Board for the Rosalind Franklin Institute and Scientific Advisory Board for Grey Wolf Therapeutics